Precision Medicine in Fatty Liver Disease: How to Identify the Patient Who Develops Steatohepatitis Using Omics Techniques
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Steatosis, without fibrosis or inflammation
研究概览
简要总结
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metabolic syndrome
- •Liver steatosis detected on transient hepatic elastography performed in the last 12 months
- •Steatosis with or without fibrosis confirmed histologically in a liver biopsy performed in the last 12 months
排除标准
- •Concurrent liver disease (other than NAFLD)
- •Chronic or prolonged use of any potential hepatotoxic drug or substance
- •HIV infection
- •Cancer (except basal cell carcinoma)
结局指标
主要结局
Steatosis, without fibrosis or inflammation
时间窗: 12 months
Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation
Steatohepatitis, with fibrosis
时间窗: 12 months
Patients with non-alcoholic fatty liver disease presenting with steatosis and degree \>1 of liver fibrosis
次要结局
未报告次要终点
研究者
Guilherme Rezende
Associate Professor
Universidade Federal do Rio de Janeiro